This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D64.4 | Synonyms: congenital dyserythropoietic anemia, CDA Type I/II/III, Congenital dyserythropoietic anaemia (various types), ineffective erythropoiesis anemia
The Korean term for this condition is a translation of "dyserythropoietic anaemia" and refers to a group of congenital anemias whose core features are dysplasia (dyserythropoiesis) and ineffectiveness of red cell production. In 1966–1968, Heimpel, Wendt, Crookston and other European hematologists found common bone marrow morphologic features in previously unclassified anemia cases and proposed an independent disease category called CDA (congenital dyserythropoietic anaemia).
The type I, II and III classification system first proposed by Heimpel and Wendt in 1968 was based on bone marrow morphology, electron microscopic findings and serologic characteristics. Crookston et al. subsequently described a unique serologic feature of CDA type II called HEMPAS (Hereditary Erythroblastic Multinuclearity with Positive Acidified Serum test).
With advances in molecular genetic research since the 2000s, the causative genes of each CDA subtype began to be identified. The discoveries of CDAN1 for CDA type I (2002), SEC23B for CDA type II (2009) and KIF23 for CDA type III (2012) are major milestones in this field. Subsequently KLF1 (CDA type IV), GATA1 (CDAX type), C15ORF41 (an additional cause of CDA type I) and others were discovered in turn.
Historically, as cases reported as a single disease accumulated, CDA has come to be understood as a disease group with multiple genetic causes. ICD-10 code D64.4 covers this entire disease group, and the Korean name, dyserythropoietic anemia (congenital), emphasizes that abnormal red cell production in the bone marrow is present congenitally.
CDAN1 gene variants: dysfunction of the codanin-1 protein causes defects in DNA replication and maintenance of chromatin structure. C15ORF41 gene variants: an additional cause (about 15–20%), dysfunction of a protein that functions as a DNA endonuclease. Both gene variants follow an autosomal recessive inheritance pattern.
SEC23B gene variants: dysfunction of a component of the COPII vesicle coat complex. COPII vesicles are responsible for protein transport from the endoplasmic reticulum (ER) to the Golgi apparatus, and loss of SEC23B function causes abnormal N-glycosylation of red cell membrane glycoproteins and abnormal cell membrane structure. Autosomal recessive inheritance.
KIF23 gene variants: dysfunction of the MKLP-1 kinesin motor protein. It regulates completion of the midzone spindle in telophase, and its dysfunction leads to failure to complete cytokinesis of erythroblasts, forming multinucleated giant cells.
| Subtype | Causative gene | Mode of inheritance | Populations with founder effects |
|---|---|---|---|
| CDA type I | CDAN1, C15ORF41 | Autosomal recessive | Ashkenazi Jews (CDAN1 p.R1042W) |
| CDA type II | SEC23B | Autosomal recessive | Southern Italy, Mediterranean region (p.E109K) |
| CDA type III | KIF23 | Autosomal dominant | Northern Sweden (p.R780Q) |
| CDA type IV | KLF1/EKLF | Autosomal dominant | No particular population bias |
| CDAX | GATA1 | X-linked | Sporadic |
Clinical severity varies even with the same gene variant, reflecting additional gene variants (modifier genes), environmental factors and genotype-phenotype complexity. For SEC23B variants, clinical severity varies with the variant type (missense, nonsense, splice variants).
CDAN1 regulates erythroid differentiation through interaction with the histone chaperone CAF-1. SEC23B is a COPII vesicle coat protein involved in ER-to-Golgi protein transport and membrane glycoprotein processing. KIF23 is the MKLP-1 kinesin protein, related to the spindle checkpoint during cell division. KLF1 is an erythroid-specific transcription factor that regulates blood cell differentiation as a whole.
Congenital dyserythropoietic anemia (CDA) is an ultra-rare disease with fewer than an estimated 1,000 registered patients worldwide. The actual prevalence is likely to be underestimated because of diagnostic difficulty.
CDA type II accounts for 60–70% of all CDA and is the most common. The frequency of CDA type II is relatively high in the Mediterranean region, such as Italy and Spain, and in the Middle East. CDA type I accounts for 20–30% of the total and is frequent in Ashkenazi Jews (carrier frequency about 1/60). CDA type III is a very rare subtype reported in only a few dozen families worldwide.
CDA is a congenital disease, and the timing of symptom onset varies by subtype and between individuals. In severe forms, severe anemia requiring transfusion appears in the neonatal period or infancy. In mild CDA type II, the diagnosis is sometimes not made until adulthood.
CDA patients in Korea are identified through very few case reports, and there are no accurate national prevalence statistics. Specialized care for rare blood diseases is provided mainly through the rare disease helpline and major tertiary care centers. With advances in genomic analysis technology, the number of diagnosed cases in Korea is gradually increasing.
Ineffective erythropoiesis is the common mechanism in all CDA subtypes. Normally 8–16 cells are produced from a proerythroblast for red cells to reach final maturity, but in CDA, dysplastic cells in this process are abnormally destroyed within the bone marrow.
The CDAN1 protein (codanin-1) binds the B subunit (CHAF1B) of the histone chaperone CAF-1 (Chromatin Assembly Factor-1) and assists chromatin assembly after DNA replication. With loss of function, defects in chromatin structure formation occur in erythroblasts, causing the formation of intranuclear cavities ("Swiss cheese" dysplasia) and internuclear chromatin bridges.
When SEC23B function is abnormal, protein transport via COPII vesicles decreases, and red cell membrane glycoproteins that should normally be processed in the Golgi apparatus are abnormally glycosylated. This results in abnormal N-glycosylation of band 3 protein and changes in the molecular weight of CD44 and band 4.5, and formation of double plasma membranes (cisternae) is characteristic.
KIF23 (MKLP-1) is located at the central spindle and is involved in spindle completion and initiation of cytokinesis during cell division. With dysfunction, cytokinesis cannot be completed, forming giant cells (gigantoblasts) containing up to 12 nuclei.
In all CDA subtypes, anemia due to ineffective erythropoiesis causes an increase in EPO, which leads to iron overload through bone marrow hyperplasia and increased iron absorption in the small intestine (hepcidin suppression).
Fatigue, reduced exercise tolerance, pallor, and dizziness are common symptoms. Jaundice (scleral icterus) reflects increased indirect bilirubin due to ineffective erythropoiesis. Abdominal pain due to gallstones may recur.
In severe CDA, severe anemia and jaundice occur in the neonatal period and immediate transfusion may be needed. Cases of extremely severe CDA presenting as hydrops fetalis are also rarely reported. Some cases of CDA type I are accompanied by congenital malformations such as finger and toe malformations, which can be a diagnostic clue.
Pallor, scleral icterus, splenomegaly and hepatomegaly are the main physical findings. With progression of iron overload, bronze pigmentation of the skin may appear. Finger and toe malformations and nail abnormalities are observed in some cases of CDA type I. In CDA type III, vascular abnormalities may appear on funduscopic examination in adulthood.
CBC: mild to moderate anemia (Hb commonly in the 7–12 g/dL range), reticulocyte count inappropriately low or mildly increased, MCV normal to elevated (macrocytosis). Biochemistry: elevated indirect bilirubin, elevated LDH (an indicator of ineffective erythropoiesis), decreased haptoglobin, elevated serum ferritin, increased transferrin saturation. Serum erythropoietin: excessively elevated relative to the degree of anemia (reflecting ineffective erythropoiesis).
| Subtype | Light microscopy | Electron microscopy | Serology |
|---|---|---|---|
| CDA type I | Internuclear chromatin bridges, binucleated erythroblasts | Chromatin cavities ("Swiss cheese"), nuclear membrane–endoplasmic reticulum abnormalities | Ham test negative |
| CDA type II | Binucleated to multinucleated (up to 5 nuclei) erythroblasts | Double plasma membrane cisternae | Ham test positive, strong i antigen expression |
| CDA type III | Giant multinucleated erythroblasts with up to 12 nuclei (gigantoblasts) | Failure to complete nuclear division | Generally normal |
CDA should be suspected in the following situations: ① unexplained chronic anemia in childhood to adolescence; ② anemia with a reticulocyte count that is low relative to hemolysis markers (elevated indirect bilirubin, LDH); ③ anemia with splenomegaly and jaundice; ④ anemia requiring repeated transfusions (negative family history); ⑤ patients with similar anemia in the family.
CBC and absolute reticulocyte count; peripheral blood smear (to check red cell morphology, macrocytes, abnormal forms); hemolysis markers (LDH, bilirubin, haptoglobin, urine bilirubin); serum ferritin and iron saturation (initial screening for iron overload).
Ham test (acidified serum hemolysis test): limited sensitivity but usable as low-cost screening. Flow cytometry (CD55/CD59, i antigen): distinguishes CDA type II from PNH.
Subtype-specific dysplastic erythroblasts are identified on light and electron microscopic examination of bone marrow aspirate and biopsy. Electron microscopy (EM) is very useful for distinguishing CDA subtypes and is essential for identifying the chromatin cavities of CDA type I and the double plasma membrane of CDA type II.
NGS-based rare anemia/red cell disorder panel: includes CDAN1, C15ORF41, SEC23B, KIF23, KLF1, GATA1, PIEZO1 and others. Targeted gene sequencing (Sanger sequencing): when a specific subtype is suspected. MLPA or array CGH when a large deletion is suspected.
Hemoglobin electrophoresis/HPLC (to exclude thalassemia and sickle cell anemia); red cell enzyme tests (to exclude G6PD deficiency and pyruvate kinase deficiency); direct antiglobulin test (DAT, to exclude immune hemolysis); flow cytometry (to exclude PNH); cytogenetic testing and somatic variant NGS to exclude MDS.
When CDA has been confirmed in the family, prenatal diagnosis is possible in subsequent pregnancies through fetal DNA genetic testing via CVS or amniocentesis.
Packed red cell transfusion is given for moderate or worse anemia (Hb <7–8 g/dL) or when symptoms are present. Transfusions are given as few times as possible, targeting Hb 9–10 g/dL. Extended blood group matching is performed to prevent alloimmunization due to blood group mismatch.
Regardless of transfusion dependence, iron overload due to ineffective erythropoiesis progresses slowly. Iron chelation is started at serum ferritin >1,000 μg/L or transferrin saturation >45% or higher. Oral agents: deferasirox, deferiprone. Injectable agent: deferoxamine (subcutaneous or intravenous). Regular monitoring of iron overload with liver MRI T2* and cardiac MRI T2*.
In CDA type I, subcutaneous injection of interferon alfa-2a or 2b (three times a week) has been reported to reduce ineffective erythropoiesis and raise Hb. The response rate is about 60–70%, and monitoring for adverse effects (flu-like symptoms, cytopenias) is needed.
Splenectomy is performed for increased transfusion requirements due to hypersplenism or severe splenomegaly, and laparoscopic cholecystectomy for symptomatic cholelithiasis. After splenectomy, preventive management of the risks of thrombosis (including portal vein thrombosis) and sepsis is needed.
In severe CDA type I and other severe CDA, when transplantation from an HLA-matched donor is possible, allogeneic HSCT is considered, particularly in young patients with high transfusion dependence and progressive iron overload. Luspatercept, an inhibitor of ineffective erythropoiesis, is also under clinical study in CDA.
Cardiac dysfunction, liver cirrhosis and endocrine complications (diabetes, osteoporosis, hypogonadism) due to iron overload are the main long-term complications. Normalization of life expectancy is possible in patients who receive appropriate iron chelation therapy. With successful HSCT, a curative outcome can be expected.
Every 3–6 months: CBC, serum ferritin, LDH, bilirubin; every 1–2 years: liver MRI T2* (quantification of iron overload), echocardiography, bone density testing, endocrine function tests, ophthalmologic examination (CDA type III).
Because congenital dyserythropoietic anemia is a genetic disease, genetic counseling must be provided after the diagnosis is confirmed. In autosomal recessive forms (CDA types I and II), counseling covers the 25% risk of each sibling being affected and the 100% carrier risk. In the autosomal dominant form (CDA type III), counseling covers the 50% risk of disease in children of an affected parent.
In high-risk couples in whom the causative gene variant has been identified, prenatal genetic testing via CVS or amniocentesis, or preimplantation genetic testing (PGT-M) with in vitro fertilization, can be performed. Such choices should be preceded by sufficient medical and ethical counseling.
Avoid taking unnecessary iron supplements, be cautious about excessive vitamin C intake, and moderate excessive consumption of red meat. Measure serum ferritin regularly and adhere to the criteria for starting iron chelation.
After splenectomy, vaccinate against encapsulated bacteria (pneumococcus, meningococcus, Haemophilus influenzae type b). Prophylactic penicillin (pediatric patients after splenectomy). Visit a medical facility immediately in case of fever.